High levels of circulating IL-6 and IL-8 are biomarkers for severe metastatic prostate cancer in humans (37, 38), and relative levels of these immune mediators are considered to be surrogates for tumor burden (39, 40). Here, IL6 is linked to metastatic prostate carcinoma.